Digital health company Adherium Limited (ASX: ADR) has signed a collaboration agreement with US-based Allergy Partners to transform asthma management for its more than 300,000 patients across 130 sites in 20 states.
Allergy Partners is the largest allergy and asthma practice in the US. It will integrate Adherium’s leading-edge Hailie platform consisting of a growing portfolio of sensor technology, user app, clinician portal, and cloud-based data solution into its care approach. The end-to-end Hailie platform will enable Allergy Partners patients to better manage their asthma, and its clinicians to tailor care with data supporting medication adherence, behavioural influencing, escalations, and interventions while enable billing for remote patient management.
Adherium welcomes this ground breaking partnership with Allergy Partners – part of our push to accelerate commercialisation in the US through strategic, large-scale partnerships across health care systems. Adherium and Allergy Partners are combining their expertise to make a powerful impact to improve patient lives with benefits for all stakeholders,” CEO, Rick Legleiter, said,
Allergy Partners’ Chief Medical Officer, William McCann, MD, called the Hailie platform, “a game-changer enabling patients to actively manage their conditions, aligning perfectly with Allergy Partners’ mission to improve allergy and asthma patients’ lives.”
Hailie’s cloud-based platform captures and shares information from Bluetooth enabled sensors that wrap around a patient’s prescribed inhaler. Hailie’s clinically proven, unique sensors capture when and how an inhaler is being used, radically improving adherence and patient self-management. This enables timely interventions and tailored treatments to improve health outcomes and greatly reduce hospital admissions.
Following four US FDA 510(k) market clearances of the next generation Hailie sensors, Adherium progressed on its regulatory strategy to 79% coverage for sensors capturing physiological data such as inhalation flow rate, and 91% coverage for adherence tracking of US top 20 branded inhaler medications by sales volume. Hailie is the only FDA 510(k) cleared drug agnostic digital sensor available today to offer physiological data insights on inhaler technique.
Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium gets paid for sensor sales and by receiving monthly, per patient fees for generating and transmitting respiratory data.
Adherium and Allergy Partners have agreed an implementation plan with an initial roll out to three US states this quarter with continued expansion to more locations across its markets later this calendar year. Demonstrating its commitment to the collaboration, Allergy Partners hired a new employee that started this week as the internal program manager at the corporate headquarters to champion the implementation. Likewise, Adherium is investing by expanding its US-based customer service and application support team with new staff onboarded this month. To support the scale-up there is sufficient sensor stock in the US to satisfy demand and Adherium’s contract manufacturer has the ability to ramp-up production as required.
